Professional Summary
Professional Overview
JS Cleiftie is a seasoned finance and business executive with extensive experience in the biopharmaceutical industry. As the Chief Business Officer and Chief Financial Officer at NextRNA Therapeutics, he leverages his deep expertise in strategic business development, financial management, and cross-functional leadership to drive the company's growth and success.
Experience Summary
Current Role
In his current role as Chief Business Officer and Chief Financial Officer at NextRNA Therapeutics, JS Cleiftie is responsible for overseeing the company's business strategy, financial operations, and cross-functional collaboration. He plays a crucial part in shaping the organization's strategic vision, securing partnerships and licensing agreements, and ensuring financial stability and growth.
Career Progression
Prior to his current position, JS Cleiftie served as the Chief Business Officer and Head of Finance at NextRNA Therapeutics, where he played a pivotal role in the company's business development and financial management. Before that, he held the role of Chief Business Officer at ERYTECH Pharma, where he was instrumental in securing key partnerships and driving the company's global expansion. Earlier in his career, JS Cleiftie held leadership positions at SANOFI and Innoven Partners, where he demonstrated his expertise in business development, global licensing, and healthcare venture capital.
Academic Background
JS Cleiftie holds a strong educational background, having completed his studies at a prestigious institution. His academic achievements and specialized training have equipped him with the necessary knowledge and skills to excel in the biopharmaceutical industry.
Areas of Expertise
- Strategic business development and licensing
- Financial management and operations
- Cross-functional leadership and collaboration
- Venture capital and healthcare investments
- Regulatory compliance and risk management
Professional Impact
Throughout his career, JS Cleiftie has made significant contributions to the biopharmaceutical industry. He has successfully negotiated and implemented numerous partnerships, secured licensing agreements, and driven the growth of the organizations he has been a part of. His expertise in financial management and business strategy has been instrumental in ensuring the long-term sustainability and profitability of the companies he has served.
Conclusion
With his extensive experience, deep industry knowledge, and proven track record of success, JS Cleiftie is poised to continue his impactful career at NextRNA Therapeutics. As the Chief Business Officer and Chief Financial Officer, he is well-equipped to navigate the complexities of the biopharmaceutical industry and contribute to the company's continued growth and innovation.
